A
The startup develops AI services for analyzing hematoxylin and eosin (HE) stained tissue slides, utilizing advanced image analysis techniques to extract critical medical information not visible to the human eye. This technology eliminates the need for immunohistochemical (IHC) staining, enabling pathologists to more accurately predict breast cancer treatment and prognosis.
Updated 4 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops AI services for analyzing hematoxylin and eosin (HE) stained tissue slides, utilizing advanced image analysis techniques to extract critical medical information not visible to the human eye. This technology eliminates the need for immunohistochemical (IHC) staining, enabling pathologists to more accurately predict breast cancer treatment and prognosis.